NanoViricides plans Phase II trial of NV-387 for measles
NNVC•NanoViricides said it is developing a Phase II trial protocol for NV-387 in measles, targeting FDA review; the drug remains investigational and has no FDA approval for any disease.
1. Trial development
NanoViricides announced on Nov. 10, 2026, that it is developing a Phase II trial protocol for NV-387 in measles, targeting FDA review. The company said previously reported animal studies showed antiviral activity against measles, and a completed juvenile mouse study found no treatment-related toxicity. NV-387 is already in Phase II trials for Ebola and mpox.
2. Rare disease designations
The company said FDA orphan drug designation offers potential tax credits, fee exemptions and seven years of market exclusivity following approval. Rare pediatric disease designation could yield a transferable priority review voucher upon successful marketing approval, subject to required conditions.
